Marshall Edwards Inc.

	Current News News Archive


Thursday, 21 January 2010		print
Analysis of Ovature trial to proceed following database lock view full article >>>
Tuesday, 08 December 2009		print
Presentations made at the 2009 Annual Meeting of Shareholders. view full article >>>
Tuesday, 08 December 2009		print
Chairman's address to the annual meeting of shareholders view full article >>>
Tuesday, 01 December 2009		print
Marshall Edwards appoints acting CEO view full article >>>
Tuesday, 29 September 2009		print
Marshall Edwards' NV-128 demonstrates good safety profile and high anti-cancer activity in vivo view full article >>>
Tuesday, 22 September 2009		print
Marshall Edwards receives NASDAQ notice of minimum bid price non-compliance view full article >>>
Monday, 21 September 2009		print
Latest Marshall Edwards corporate presentation view full article >>>
Wednesday, 05 August 2009		print
Marshall Edwards licenses anti-cancer compound NV-128 from Novogen Limited view full article >>>
Tuesday, 07 July 2009		print
Researchers discover that penoxodiol kills rapidly proliferating T-cells view full article >>>
Wednesday, 17 June 2009		print
Independent DMC reviews arrangement for data analysis of the Ovature trial view full article >>>
Wednesday, 15 April 2009		print
Interview with Marshall Edwards' CEO, Mr Christopher Naughton, view full article >>>
Tuesday, 14 April 2009		print
Marshall Edwards, Inc., to undertake analysis of Ovature trial view full article >>>
Thursday, 19 March 2009		print
Biotech analyst joins board of directors of Marshall Edwards, Inc. view full article >>>
Wednesday, 18 March 2009		print
triphendiol safety data clears the way for it to be studied further fo pancreatic cancer view full article >>>
Friday, 27 February 2009		print
An interview with Professor Alan Husband, Marshall Edwards' Research Director. view full article >>>
Tuesday, 24 February 2009		print
Yale researchers present results of phase II phenoxodiol clinical trial in prostate cancer patients at ASCO 2009 Genitourinary Cancers Symposium view full article >>>
Friday, 16 January 2009		print
Presentation made at the 27th Annual JPMorgan Healthcare Conference view full article >>>
Wednesday, 14 January 2009		print
Marshall Edwards, Inc., to present at the 27th Annual JPMorgan Healthcare Conference. view full article >>>
Friday, 09 January 2009		print
An interview with Professor Alan Husband, Marshall Edwards' Research Director view full article >>>
Wednesday, 07 January 2009		print
Marshall Edwards granted an IND for triphendiol view full article >>>
Monday, 01 December 2008		print
Marshall Edwards files IND application for triphendiol view full article >>>
Wednesday, 12 November 2008		print
MSHL's Independent Data Monitoring Committee recommends Ovature trial continue view full article >>>
Wednesday, 13 August 2008		print
Presentation made at the Canaccord Adams 28th Annual Global Growth Conference view full article >>>
Monday, 11 August 2008		print
Marshall Edwards, Inc., to present at Canaccord Adams 28th Annual Global Growth Conference view full article >>>
Wednesday, 30 July 2008		print
Marshall Edwards, Inc.,raises $10,000,000 in public offering view full article >>>
Thursday, 26 June 2008		print
Marshall Edwards, Inc., joins Russell 3000 index view full article >>>
Monday, 09 June 2008		print
Independent Data Monitoring Committee recommends Marshall Edwards Inc's Ovature trial continues view full article >>>
Thursday, 15 May 2008		print
Clinical phase l study report of Marshall Edwards' compound triphendiol to be reported in ASCO proceedings view full article >>>
Friday, 09 May 2008		print
Extended accrual time and decreased sample size for Marshall Edwards' OVATURE trial view full article >>>
Sunday, 13 April 2008		print
Marshall Edwards' investigational drug triphendiol demonstrates potent activity against biliary cancers view full article >>>
Tuesday, 25 March 2008		print
Data to be presented at AACR reveals that triphendiol may aid in the treatment of pancreatic cancer view full article >>>
Monday, 10 March 2008		print
Phenoxodiol trials highlighted at ovarian cancer action international conference view full article >>>
Tuesday, 19 February 2008		print
Additional orphan drug status granted to Marshall Edwards' investigational anti-cancer drug triphendiol (NV-196) view full article >>>
Tuesday, 22 January 2008		print
Orphan drug status granted for Marshall Edwards' investigational anti-cancer drug triphendiol (NV-196) view full article >>>
Thursday, 10 January 2008		print
Presentation made to the JPMorgan Healthcare Conference. view full article >>>
Wednesday, 09 January 2008		print
Marshall Edwards, Inc., to present at the 26th Annual JPMorgan Healthcare Conference. view full article >>>
Wednesday, 19 December 2007		print
Chairman's address to the Annual Stockholders' Meeting view full article >>>
Wednesday, 19 December 2007		print
Corporate Presentation - Annual Meeting of Shareholders 2007 view full article >>>
Monday, 29 October 2007		print
European symposium focuses on phenoxodiol as an investigational drug for ovarian cancer management view full article >>>
Tuesday, 23 October 2007		print
European symposium on phenoxodiol as an investigational drug for ovarian cancer management view full article >>>
Tuesday, 23 October 2007		print
Yale Cancer Center sponsors study of phenoxodiol for prostate cancer view full article >>>
Wednesday, 03 October 2007		print
Marshall Edwards, Inc., to present at BIO Investor Forum 2007 view full article >>>
Monday, 27 August 2007		print
First patient enrolled in Europe in Ovature Phase III ovarian cancer trial view full article >>>
Tuesday, 21 August 2007		print
Marshall Edwards Newsletter - August, 2007 view full article >>>
Monday, 13 August 2007		print
Newly published research indicates the potential of phenoxodiol to protect against Neuropathy view full article >>>
Monday, 06 August 2007		print
Marshall Edwards, Inc., raises $16.4m in private equity financing view full article >>>
Monday, 04 June 2007		print
Company Announcement view full article >>>
Friday, 01 June 2007		print
Ovature Phase III trial enrolls first US patient view full article >>>
Tuesday, 01 May 2007		print
New research shows that investigational drug phenoxodiol targets cancer protein, causing cancer cell death view full article >>>
Thursday, 29 March 2007		print
New Board appointment at Marshall Edwards, Inc. view full article >>>
Friday, 02 February 2007		print
Corporate presentation made to the JPMorgan 25th Annual Healthcare Conference view full article >>>
Tuesday, 09 January 2007		print
The Marshall Edwards, Inc. presentation at the 25th Annual JPMorgan Healthcare Conference to be webcast view full article >>>
Thursday, 04 January 2007		print
Marshall Edwards, Inc. to present at the 25th Annual JPMorgan Healthcare Conference view full article >>>
Tuesday, 12 December 2006		print
Corporate Presentation - Annual Meeting of Shareholders 2006 - H Kluger, M.D. view full article >>>
Tuesday, 12 December 2006		print
Corporate Presentation - Annual Meeting of Stockholders 2006 - Mr Christopher Naughton view full article >>>
Tuesday, 12 December 2006		print
Corporate Presentation - Annual Meeting of Stockholders 2006 - Professor Alan Husband view full article >>>
Thursday, 30 November 2006		print
Marshall Edwards, Inc., Newsletter view full article >>>
Tuesday, 28 November 2006		print
Marshall Edwards Inc appoints Professor Bryan Williams as Chairman view full article >>>
Monday, 27 November 2006		print
First patient treated in Phase III ovarian cancer trial view full article >>>
Wednesday, 08 November 2006		print
Rodman & Renshaw presentation - November 8, 2006 view full article >>>
Monday, 30 October 2006		print
Marshall Edwards to present at the Rodman & Renshaw Conference view full article >>>
Monday, 30 October 2006		print
Marshall Edwards appoints JP Morgan as financial advisor view full article >>>
Monday, 25 September 2006		print
Presentation made to the UBS Global Life Sciences Conference September 25, 2006. view full article >>>
Tuesday, 19 September 2006		print
Marshall Edwards Inc to present at the UBS Global Life Sciences Conference. view full article >>>
Monday, 18 September 2006		print
Early study provides evidence that investigational drug phenoxodiol targets prostate cancer protein. view full article >>>
Wednesday, 12 July 2006		print
Marshall Edwards raises a further $4m plus a line of equity credit view full article >>>
Wednesday, 12 July 2006		print
Marshall Edwards raises $14m in private equity view full article >>>
Tuesday, 06 June 2006		print
Marshall Edwards renegotiates phenoxodiol Licence Agreement view full article >>>
Friday, 19 May 2006		print
Marshall Edwards Newsletter view full article >>>
Tuesday, 16 May 2006		print
Marshall Edwards achieves special protocol assessment and agreement with the FDA view full article >>>
Monday, 15 May 2006		print
Marshall Edwards licences two anti cancer compounds from Novogen view full article >>>
Tuesday, 04 April 2006		print
Presentation made to the CIBC Biotechnology conference view full article >>>
Friday, 31 March 2006		print
Marshall Edwards presents at CIBC Conference view full article >>>
Wednesday, 29 March 2006		print
Yale researchers find phenoxodiol restores chemo sensitivity in some women with ovarian cancer view full article >>>
Wednesday, 29 March 2006		print
Appointment of Governor creates board vacancy at MSHL view full article >>>
Wednesday, 22 February 2006		print
Presentation made to the BioCEO & Investor Conference -Feb 2006 view full article >>>
Tuesday, 17 January 2006		print
Application for cancellation of AIM admission view full article >>>
Friday, 30 December 2005		print
Corporate presentation - Annual Meeting of Stockholders 2005 view full article >>>
Tuesday, 29 November 2005		print
Phenoxodiol in joint trial with Sanofi-Aventis at Yale view full article >>>
Thursday, 17 November 2005		print
Poster presented at the AACR-NCI-EORTC meeting view full article >>>
Thursday, 17 November 2005		print
Phenoxodiol delays tumor progression in late stage hormone refractory prostate cancer view full article >>>
Thursday, 17 November 2005		print
Researchers report anti-cancer responses for cervical cancer view full article >>>
Monday, 24 October 2005		print
Researchers report that phenoxodiol is producing significant anti-cancer responses view full article >>>
Friday, 06 May 2005		print
Rodman & Renshaw presentation - 4 May 2005 view full article >>>
Monday, 07 March 2005		print
Pivotal trial for chemo resistant ovarian cancer expedited view full article >>>
Wednesday, 26 January 2005		print
FDA grants fast track designation for oral phenoxodiol view full article >>>
Monday, 24 January 2005		print
Phenoxodiol reverses chemo-resistance to docetaxel view full article >>>
Thursday, 23 December 2004		print
Corporate presentation - Annual Meeting of Stockholders 2004 view full article >>>
Monday, 22 November 2004		print
Oral phenoxodiol reported to slow disease progression in late stage prostate cancer patients view full article >>>
Thursday, 04 November 2004		print
FDA grants Fast Track Designation for phenoxodiol view full article >>>
Monday, 14 June 2004		print
New site announced for the ovarian cancer trial with phenoxodiol view full article >>>
Monday, 17 May 2004		print
The University of Sydney honors Marshall Edwards, Inc., Chairman view full article >>>
Wednesday, 21 April 2004		print
Marshall Edwards, Inc., commences new ovarian cancer trial at Yale view full article >>>
Wednesday, 31 March 2004		print
Marshall Edwards, Inc. confirms 4 studies at AACR view full article >>>
Friday, 26 March 2004		print
Marshall Edwards, Inc., confirms the 4 abstracts for the AACR meeting view full article >>>
Monday, 08 March 2004		print
Marshall Edwards, Inc., commences renal cancer trial view full article >>>
Sunday, 22 February 2004		print
Marshall Edwards, Inc., commences clinical trial in cervical cancer at Yale view full article >>>
Monday, 09 February 2004		print
Marshall Edwards, Inc., reports Yale study partial results MEI Yale study partial results view full article >>>
Friday, 23 January 2004		print
An interview with the President of Marshall Edwards, Inc. view full article >>>
Thursday, 18 December 2003		print
Marshall Edwards, Inc., announces pricing of IPO view full article >>>
Thursday, 25 September 2003		print
Marshall Edwards Inc applies to list on Nasdaq SmallCap market view full article >>>
Friday, 29 August 2003		print
Marshall Edwards Inc Financial Statements view full article >>>
Monday, 04 August 2003		print
Marshall Edwards Inc. appoints a new Director view full article >>>
Tuesday, 17 June 2003		print
IND appoval from FDA for oral phenoxodiol and a second study commences at Yale view full article >>>

Contact Details

Marshall Edwards, Inc.
140 Wicks Road
North Ryde NSW 2113
Australia

T: +61 2 8877 6196
F: +61 2 9878 8474

.	home : about us. : about phenoxodiol : the technology : newsroom : : how to invest : contact details : credits : email Marshall Edwards Inc. 2001 ©